Abstract: A model training method and device are provided. The method is applied to an OAM entity and includes: obtaining at least one wireless access network device group by grouping a plurality of wireless access network devices sending model subscription requests, the wireless access network device group including a first number of wireless access network devices; determining a first number of model training structures corresponding to the first number of wireless access network devices, and determining a first number of unique model layers according to the first number of model training structures; and sending, to the first number of wireless access network devices, structural parameters of the first number of unique model layers.

Abstract: A method for transmitting indication information, includes: determining a discontinuous reception mode of a user equipment according to service data traffic and channel state information of the user equipment in a current discontinuous reception period; and transmitting first indication information to the user equipment, where the first indication information is used to indicate the discontinuous reception mode.

Abstract: The present invention relates to a chemical coupling linker and use thereof, and a bioactive conjugate prepared by the chemical coupling linker. The present invention also relates to use of the bioactive conjugate in the preparation of a drug for the prevention or treatment of tumor diseases.

Abstract: The present invention relates to the use of a medicament in treatment of a tumor disease. In particular, the present invention provides the use of a biologically active conjugate represented by formula (I) in treatment of a tumor disease. The tumor disease particularly and preferably refers to an unresectable locally advanced or metastatic solid tumor that is refractory according to existing treatment standards, including but not limited to breast cancer, gastric cancer, lung cancer, ovarian cancer, urinary tract epithelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer, and brain tumor.

Abstract: Methods, system, and non-transitory processor-readable storage medium for a test selection system are provided herein. An example method includes selecting, by a test selection system, a regression test case from a plurality of regression test cases in a software testing lifecycle system. The test selection system determines a product release weight associated with the regression test case, where the product release weight incorporates new features associated with a product release. The test selection system obtains a regression test case value for the regression test case by applying the product release weight. The test selection system selects the regression test case for use in regression testing for the product release, based on the regression test case value and executes the regression test case on a system.

Abstract: Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Abstract: Storage processes are described. For instance, dumping of cache data in a memory table at a source directory table partition in a source container group is stopped in response to receiving a close signal. A notification for creating a target directory table partition is sent to a target container group, the notification including a checkpoint at the source directory table partition. The cache data in the memory table is sent to the target container group, and the source container group is closed in response to a determination that an ownership of the target directory table partition is updated to the target container group. A rescheduling and/or upgrading solution is thus proposed for a source container group, so that the source container group is still in a service state during the rescheduling and/or upgrading solution, which improves the performance of storage services and reduces the data unavailable time.

Abstract: An apparatus comprises a processing device configured to determine syncing progress metrics for replication sessions established between a source and a destination storage system, each of the replication sessions being associated with a recovery point objective and having an assigned bandwidth quota. The processing device is also configured to identify whether a first replication session is not expected to meet its associated first recovery point objective based at least in part on its determined first syncing progress metric and whether at least a second replication session is expected to meet its associated second recovery point objective based at least in part on its determined second syncing progress metric. The processing device is further configured, responsive to identifying the first and second replication sessions, to update a first assigned bandwidth quota for the first replication session and a second assigned bandwidth quota for the second replication session.

Abstract: Dynamic snapshot scheduling techniques are provided using storage system metrics. One method comprises obtaining a schedule for generating snapshots of a portion of a storage system; automatically adjusting snapshot generation parameters in the schedule based on: (i) a current storage pool usage metric, (ii) an input/output metric of at least one storage resource in the portion of the storage system, (iii) a measure of snapshots in a destroying state, and/or (iv) a measure of a number of created snapshots; and initiating a generation of a snapshot of the storage system portion in accordance with the adjusted schedule. A snapshot generation frequency may be increased in response to an increase of: the current storage pool usage metric, the number of snapshots in the destroying state, and/or the number of created snapshots. A snapshot generation frequency may be decreased in response to an increase of the I/O metric of the at least one storage resource.

Abstract: Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Abstract: Storage processes are described. For instance, dumping of cache data in a memory table at a source directory table partition in a source container group is stopped in response to receiving a close signal. A notification for creating a target directory table partition is sent to a target container group, the notification including a checkpoint at the source directory table partition. The cache data in the memory table is sent to the target container group, and the source container group is closed in response to a determination that an ownership of the target directory table partition is updated to the target container group. A rescheduling and/or upgrading solution is thus proposed for a source container group, so that the source container group is still in a service state during the rescheduling and/or upgrading solution, which improves the performance of storage services and reduces the data unavailable time.

Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Abstract: Automatic file system capacity management techniques are provided using file system utilization prediction. One method comprises obtaining input data representing a utilization of a storage capacity of a file system of a given storage system; predicting a future utilization of the storage capacity of the file system based on a portion of the obtained input data; and automatically adjusting the storage capacity of the file system based at least in part on a result of a comparison of the predicted utilization of the storage capacity to a current utilization of the storage capacity. The comparison of the predicted utilization to a current utilization of the storage capacity may comprise comparing the current utilization of the storage capacity to the predicted utilization of the storage capacity for at least first and second time periods following a current time period to determine a trend of the utilization of the storage capacity.

Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: Aspects of the invention can provide a method for configuring a discontinuous reception (DRX) parameter, which method is applied to a base station. The method can include, according to first discontinuous reception (DRX) transmission feature data, configuring a discontinuous reception (DRX) parameter for a terminal, wherein the first discontinuous reception (DRX) transmission feature data is discontinuous reception (DRX) transmission feature data for discontinuous reception (DRX) transmission performed by the terminal at historical moments.

Abstract: The invention provides methods for treating a source oil phase consisting of heavy oil, bitumen, a mixture of heavy oil and bitumen, a mixture of solvent and heavy oil or bitumen or both. The method comprises: introducing the source oil phase to a heated lower section of a device to provide an interior source oil phase; heating the interior source oil phase so as to thermally separate a light oil phase component therefrom and provide a vaporized light oil; and condensing the vaporized light oil phase on one or more internal cooling fins housed within the upper section of the device, to provide a condensed light oil phase liquid, wherein the internal cooling fins are angled so as to direct the condensed light oil phase liquid downwardly to a light end collection system.

Abstract: Provided in the present invention are a salt of a benzothiazole compound as represented by formula I and a crystal form and the use thereof. The salt is selected from pamoate and palmitate. Further provided is the use of the salt of the compound of formula I and the crystal form thereof in the preparation of a drug for treating Parkinson's disease and restless leg syndrome.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Related is an anti-CLDN 18.2 antibody-drug conjugate, preparation method and use thereof. The antibody-drug conjugate and the composition thereof is capable of effectively binding CLDN 18.2 and inhibiting the growth of Claudin 18.2 positive tumors. Further related is a pharmaceutical composition comprising the antibody-drug conjugate or the composition, and use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating tumors.